A panel of differentially methylated regions enable prognosis prediction for colorectal cancer

Genomics. 2021 Sep;113(5):3285-3293. doi: 10.1016/j.ygeno.2021.07.010. Epub 2021 Jul 21.

Abstract

We aim to identify a panel of differentially methylated regions (DMRs) for predicting survival outcomes for patients with CRC from the TCGA (n = 393). Four DMRs (MUC12, TBX20, CHN2, and B3GNT7) were selected as candidate prognostic markers for CRC. The prediction potential of selected DMRs was validated by the targeted bisulfite sequencing method in an independent cohort with 251 Chinese CRC patients. DMR methylation scores (DMSs) were constructed to evaluate the prognosis of CRC. Results of the validation cohort confirmed that higher DMSs were associated with poor overall survival (OS) of CRC, with hazard ratio (HR) value ranged from 1.445 to 2.698 in multivariable Cox models. Patients in the high prognostic index (high-PI) group showed a markedly unfavorable prognosis compared to the low-PI group in both TCGA discovery cohort (HR = 3.508, 95%CI: 2.196-5.604, P < 0.001) and independent validation cohort (HR = 1.912, 95%CI: 1.258-2.907, P = 0.002).

Keywords: Colorectal cancer; DNA methylation; Prognostic prediction; Survival analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor
  • Colorectal Neoplasms* / diagnosis
  • Colorectal Neoplasms* / genetics
  • DNA Methylation*
  • Humans
  • Prognosis
  • Sequence Analysis, DNA

Substances

  • Biomarkers, Tumor